• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Nephrology - Kidney Week 2021

November 4-7, 2021

  1. Dapagliflozin
  2. Sodium Zirconium Cyclosilicate
  3. Roxadustat
  4. REVEAL CKD
  5. Verinurad
  6. Early-Stage Development
  7. General CKD

Pdf

The effect of dapagliflozin on rate of kidney function decline in patients with chronic kidney disease (CKD): a pre-specified analysis from the DAPA-CKD trial

Pdf

Correlates and Consequences of an Acute Decline in Estimated Glomerular Filtration Rate in Response to the SGLT-2 Inhibitor Dapagliflozin

Pdf

Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease

Pdf

DAPA-CKD: A regional analysis of kidney and cardiovascular outcomes

Pdf

Effects of dapagliflozin in patients with chronic kidney disease (CKD) and albuminuria, with and without diabetes, by use and non-use of cardiovascular (CV) medications: DAPA-CKD Trial

Pdf

Effect of dapagliflozin on soluble urokinase-type plasminogen activator receptor in type 2 diabetes

Pdf

Effect of dapagliflozin on soluble urokinase-type plasminogen activator receptor in type 2 diabetes

Pdf

Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: Results from the DARE-19 randomized controlled trial

Pdf

Impact of Hyperkalemia to Disrupt Emergency and Surgical Care

Pdf

Metabolic Acidosis that eXIsts with hyperkaleMia (HK) among patients that initialIZe bindEr therapy: MAXIMIZE study

Pdf

Prevalence of Hyperkalemia (HK) and Demographics in Medicare Patients Admitted to Long-Term Care or Post-Acute Care (LTC/PAC) Settings

Html

A Multicenter Retrospective Survey Study of Facility-level Hyperkalemia Burden in China: Rationale and Design of the Visualize-HD Study

Pdf

Real World RAASi Use and Its Predictors Among Patients Initiating Sodium Zirconium Cyclosilicate

Html

Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis: A prospective Multi-Centre Cohort Study

Pdf

Racial and Ethnic Predictors of Hyperkalemia Recurrence

Pdf

Liver Disease is a Predictor of Recurrent Hyperkalemia

Html

Outpatient Treatment Patterns of Hyperkalemia in the US: The Design and Initial Findings from ZORA, an Observational Study

Pdf

The associations between hepcidin and anemia in non-dialysis-dependent patients enrolled in the roxadustat global phase 3 clinical program

Pdf

The associations between hepcidin and anemia in patients incident to dialysis enrolled in the roxadustat global phase 3 clinical program

Html

Weekly Risks of Death and Hospitalization Among Incident Patients Undergoing Dialysis

Html

Associations of Pre-Dialysis Care with Trajectories of Adverse Clinical Outcomes Among Patients Initiating Dialysis

Pdf

Effects of Roxadustat in Patients with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) AcrossAll Baseline (BL) Hemoglobin (Hb) Values

Pdf

Efficacy and Safety of Roxadustat in Patients with Anemia of Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Treated Continuously for ≥3 Years

Pdf

Roxadustat Effectively Treats Anemia in Dialysis-Dependent CKD (DD-CKD) Patients with Ferritin ≥500ng/mL

Pdf

Health-related quality of life in patients with inflammation and non-dialysis-dependent chronic kidney disease

Pdf

Prevalence of inflammation and associated healthcare resource utilization in patients with chronic kidney disease

Pdf

Effects of Roxadustat in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Across All Baseline (BL) Hemoglobin (Hb) Values

Pdf

Number Needed to Treat with Roxadustat to Avoid 1 Transfusion or Intravenous Iron Administration in Anemia of Non-Dialysis-Dependent Chronic Kidney Disease

Pdf

Efficacy and Safety of Roxadustat in Patients with Anemia of Non-Dialysis-Dependent Chronic KidneyDisease (NDD-CKD) Treated Continuously for ≥2 Years

Pdf

Roxadustat in Elderly Patients with Anemia of Chronic Kidney Disease

pdf

Efficacy and Safety of Roxadustat for the Treatment of Anemia of CKD in Patients Enrolled in the US

Pdf

Associations between Hepcidin and Laboratory Measures of Iron and Inflammation in Incident Dialysis Patients with Anemia Enrolled in the Roxadustat Global Phase 3 Program

Pdf

Associations between Hepcidin and Laboratory Measures of Iron and Inflammation in Patients with Anemia and Chronic Kidney Disease not on Dialysis in the Roxadustat Global Phase 3 Program

Pdf

DENALI: A Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Operational Learnings within US Dialysis Organizations

Pdf

REVEAL-CKD: Prevalance of Undiagnosed Early Chronic Kidney Disease in France and Japan

Pdf

Tubular urate controls intracellular lactate in the proximal tubule with implications for chronic kidney disease

Pdf

IL-33 as a novel target for the treatment of diabetic kidney disease

Pdf

In-vivo data to support induced pluripotent stem cell derived renal progenitors as potential cell therapy for kidney disease

Pdf

Molecular stratification of chronic kidney disease

Pdf

Transcriptional profiling of renal endothelial compartments during progression of murine diabetic nephropathy

Pdf

Renal cytosolic phospholipase A2 mediates acute kidney injury in humans

Pdf

A 3D vascularised tubule model improves the phenotype of cultured cells

Pdf

Physiological replication of the glomerulus using a triple culture microphysiological system.

Pdf

Machine learning models to predict cardiovascular and renal outcomes and mortality in hyperkalemic patients

Html

Estimating long-term survival rates in patients with anaemia of non-dialysis-dependent CKD: an expert elicitation

Pdf

Targeted Literature Review (TLR) Exploring Adherence to Treatments, with Potential to Extrapolate to Patients with Anemia of Chronic Kidney Disease (CKD)

Pdf

A machine learning algorithm to identify patients with possible non-dialysis-dependent chronic kidney disease

Html

Machine learning models to predict cardiovascular and renal outcomes and mortality in hyperkalemic patients

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice